January 22, 2024 11:01 AM EST
People
Pharma

In bid to ex­tend cash run­way, Cara to lay off work­ers, dis­con­tin­ue PhI­II pro­gram in chron­ic kid­ney dis­ease

Anna Brown

News Reporter

Cara Ther­a­peu­tics is cut­ting its work­force by near­ly 50% and end­ing a Phase III pro­gram in­ves­ti­gat­ing an oral ver­sion of its opi­oid pep­tide in pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times